WILLIAM R RINGO
CIK 1238325 · Chief Executive Officer · last filed 2025-06-09
WILLIAM R RINGO is a Chief Executive Officer who has filed 153 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for SNSE, was dated Jan 27, 2026. Across all open-market trades the lifetime net is −$4.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.87M
12
153
-$4.32M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASMB | Director | 1,455 | $27.27 | $39.7K | -$510.4K | 23 | 2025-06-09 |
| Sensei Biotherapeutics, Inc. (SNSE) Delisted | Director | 1,170 | $13.85 | $16.2K | $0 | 4 | 2025-05-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Chief Executive Officer | 0 | $38.00 | $0 | -$1.78M | 14 | 2021-04-19 |
| DERM | Director | 6,000 | $6.32 | $37.9K | -$165.7K | 17 | 2019-06-14 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 10,000 | $178.75 | $1.79M | -$374.3K | 16 | 2019-06-12 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 31,800 | $0.18 | $5.6K | -$1.10M | 15 | 2017-09-22 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | — | $58.70 | — | $0 | 4 | 2016-05-19 |
| ASSEMBLY BIOSCIENCES, INC. (VTUS) Delisted | Director | 20,465 | — | — | $0 | 1 | 2014-07-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 9,837 | — | — | -$400.3K | 7 | 2013-04-01 |
| PFE | Senior Vice President | 255,139 | $26.62 | $6.79M | $0 | 37 | 2010-04-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 3,000 | — | — | $0 | 2 | 2007-06-21 |
| INSPIRE PHARMACEUTICALS INC (ISPH) Delisted | Director | — | — | — | $0 | 1 | 2007-06-12 |
Recent Filings
153 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-27 | Sensei Biotherapeutics, Inc. (SNSE) Delisted | Notice (144) | −1,169 | -$11.5K | EDGAR |
| 2025-06-09 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2025-05-23 | Sensei Biotherapeutics, Inc. (SNSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | Sensei Biotherapeutics, Inc. (SNSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-30 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2023-07-12 | Sensei Biotherapeutics, Inc. (SNSE) Delisted | Grant (A) | +4,466 | $0 | EDGAR |
| 2023-05-30 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2022-03-09 | Sensei Biotherapeutics, Inc. (SNSE) Delisted | Grant (A) | +18,933 | $0 | EDGAR |
| 2021-05-24 | ASMB | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.